News

Today’s approvals follow the first FDA approval of SIMPONI ARIA in 2013 for the treatment of moderately to severely active rheumatoid arthritis (RA). The PsA and AS approvals are

The non-live, recombinant subunit vaccine has been indicated to be given intramuscularly in two doses. Shingrix, which combines glycoprotein E antigen with the AS01B adjuvant system, works by

TARGET-NASH is a longitudinal observational study that evaluates patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH). To date, TARGET-NASH has enrolled 2,423 patients at 55

As part of this agreement, the companies will advance Alnylam's HBV program and also initiate a research collaboration for the development and advancement of up to four additional

The FDA approval for Yescarta includes patients with diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma, and DLBCL resulting

Fremanezumab, which is an anti-calcitonin gene-related peptide (anti-CGRP) monoclonal antibody, is intended for the preventive treatment of migraine. The CGRP ligand is considered to be a well-validated target

The partnership will use the HemoShear’s Reveal-Tx proprietary disease modeling platform, which applies principles of physiological blood flow to tissue derived from patients. The platform will help drug

Through the PRIME initiative, Ignyta will have enhanced EMA support, including optimizing the entrectinib development pathway, potentially accelerating assessment of the Marketing Authorisation Application (MAA), and engaging in

The FDA has granted Imfinzi priority review status. The US FDA sBLA submission acceptance is an important milestone for IMFINZI in a disease state where patients need better treatment